Tags

Type your tag names separated by a space and hit enter

Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs.
Front Public Health. 2023; 11:1147489.FP

Abstract

Introduction

Social determinants of health (SDOH) are important contributors to health outcomes, and better understanding their impact on individuals diagnosed with rare, chronic diseases with high burden and unmet need is critical. Characterizing SDOH burden can help improve the design of patient support programs (PSPs), using targeted approaches to remove barriers to access.

Methods

This study used a mixed-methods strategy employing a quantitative survey, which was designed based on qualitative interviews, to understand the unmet needs and awareness/utilization of PSPs among individuals living with generalized myasthenia gravis (gMG) and experiencing SDOH barriers. The survey was completed by 38 individuals living with gMG, of which the majority were non-White/Caucasian, unemployed, low income, and enrolled in public insurance. Common SDOH challenges, awareness/utilization of available PSPs, and unmet needs were identified.

Results

Financial and mental health concerns were the most common among individuals living with gMG and experiencing SDOH barriers throughout diagnosis, accessing treatment, initiating treatment, and continuing treatment. Awareness and utilization of existing support services were low, especially when accessing treatment. Educational, financial, and personalized support with high "human touch" were commonly perceived as the most valuable resources.

Implications

To better serve the needs of individuals with gMG experiencing SDOH barriers, PSPs should use a targeted approach to offer services tailored to harder-to-reach populations. Further, providers, advocacy groups, manufacturers, and public organizations in the gMG ecosystem should strengthen collaborations with PSPs to enable individuals living with gMG to access the services they need to improve their health outcomes.

Authors+Show Affiliations

argenx US Inc., Boston, MA, United States.Department of Neurology, Houston Methodist, Houston, TX, United States.UCI Health ALS & Neuromuscular Center, University of California Irvine, Orange, CA, United States.argenx US Inc., Boston, MA, United States.argenx US Inc., Boston, MA, United States.ZS Associates, New York, NY, United States.ZS Associates, New York, NY, United States.ZS Associates, New York, NY, United States.ZS Associates, New York, NY, United States.ZS Associates, New York, NY, United States.argenx US Inc., Boston, MA, United States.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

37275500

Citation

Hughes, Tom, et al. "Impact of Social Determinants of Health On Individuals Living With Generalized Myasthenia Gravis and Implications for Patient Support Programs." Frontiers in Public Health, vol. 11, 2023, p. 1147489.
Hughes T, Anderson AEL, Habib AA, et al. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. 2023;11:1147489.
Hughes, T., Anderson, A. E. L., Habib, A. A., Perez, K., Bergin, C., Suchotliff, S., Zvosec, C., McDaniel, D., Sato, M., Whangbo, A., & Phillips, G. (2023). Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Frontiers in Public Health, 11, 1147489. https://doi.org/10.3389/fpubh.2023.1147489
Hughes T, et al. Impact of Social Determinants of Health On Individuals Living With Generalized Myasthenia Gravis and Implications for Patient Support Programs. Front Public Health. 2023;11:1147489. PubMed PMID: 37275500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. AU - Hughes,Tom, AU - Anderson,Ashley E L, AU - Habib,Ali A, AU - Perez,Kathy, AU - Bergin,Cathleen, AU - Suchotliff,Sharon, AU - Zvosec,Cecilia, AU - McDaniel,Dajzsa, AU - Sato,Mai, AU - Whangbo,Albert, AU - Phillips,Glenn, Y1 - 2023/05/19/ PY - 2023/01/18/received PY - 2023/05/05/accepted PY - 2023/6/7/medline PY - 2023/6/5/pubmed PY - 2023/6/5/entrez KW - burden KW - caregivers KW - mixed methods KW - myasthenia gravis KW - patient support services KW - patients KW - social determinants of health SP - 1147489 EP - 1147489 JF - Frontiers in public health JO - Front Public Health VL - 11 N2 - Introduction: Social determinants of health (SDOH) are important contributors to health outcomes, and better understanding their impact on individuals diagnosed with rare, chronic diseases with high burden and unmet need is critical. Characterizing SDOH burden can help improve the design of patient support programs (PSPs), using targeted approaches to remove barriers to access. Methods: This study used a mixed-methods strategy employing a quantitative survey, which was designed based on qualitative interviews, to understand the unmet needs and awareness/utilization of PSPs among individuals living with generalized myasthenia gravis (gMG) and experiencing SDOH barriers. The survey was completed by 38 individuals living with gMG, of which the majority were non-White/Caucasian, unemployed, low income, and enrolled in public insurance. Common SDOH challenges, awareness/utilization of available PSPs, and unmet needs were identified. Results: Financial and mental health concerns were the most common among individuals living with gMG and experiencing SDOH barriers throughout diagnosis, accessing treatment, initiating treatment, and continuing treatment. Awareness and utilization of existing support services were low, especially when accessing treatment. Educational, financial, and personalized support with high "human touch" were commonly perceived as the most valuable resources. Implications: To better serve the needs of individuals with gMG experiencing SDOH barriers, PSPs should use a targeted approach to offer services tailored to harder-to-reach populations. Further, providers, advocacy groups, manufacturers, and public organizations in the gMG ecosystem should strengthen collaborations with PSPs to enable individuals living with gMG to access the services they need to improve their health outcomes. SN - 2296-2565 UR - https://www.unboundmedicine.com/medline/citation/37275500/ DB - PRIME DP - Unbound Medicine ER -